News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

29 Sep, 2015, 14:00 BST Shire to Participate at the Leerink Partners 4th Annual Rare Disease Roundtable

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Phil Vickers, Head of Research and Development and Jeff Poulton, Chief Financial Officer, will...


24 Sep, 2015, 19:07 BST Appeals Court Affirms Shire's Vyvanse® (lisdexamfetamine dimesylate) Patents Are Valid Until 2023

Ruling bars generic versions of Vyvanse from entering market until patents expire Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that the Court...


21 Sep, 2015, 07:00 BST Shire Receives European Approval for INTUNIV®▼ (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents

The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced...


14 Sep, 2015, 12:03 BST Shire to Participate at Two Upcoming Investor Conferences

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Morgan Stanley Global Healthcare ...


01 Sep, 2015, 07:00 BST Shire Appoints Sara Mathew to Board of Directors

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Sara Mathew to its Board of Directors as a Non-Executive Director. Sara will also be...


25 Aug, 2015, 12:00 BST Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity

The company enters into new agreement with Sanquin Shire plc (LSE: SHP, NASDAQ: SHPG) announced today it has entered into an agreement with Sanquin...


10 Aug, 2015, 06:00 BST Shire Launches 2015 Excellence in ADHD Patient Group Awards

Online entry opens today at Shire.com/patients/patient-advocacy/patient-group-award Shire plc (LSE: SHP, NASDAQ: SHPG) today launches the second...


04 Aug, 2015, 12:30 BST Shire Proposes Combination With Baxalta to Create the Leading Global Biotech Company Focused on Rare Diseases

Strong strategic fit and industry-leading portfolio of combined company is projected to deliver immediate value creation and generate $20 billion in...


03 Aug, 2015, 12:00 BST Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset

FST-100, if approved, would be the first to treat both bacterial and viral eye infections, transforming treatment of acute conjunctivitis Shire plc...


23 Jul, 2015, 12:01 BST Shire Announces Second Quarter Earnings and Increases Full Year Non GAAP Diluted EPS Guidance to Mid-to-High Single Digit Growth

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to June 30, 2015. ...


01 Jul, 2015, 12:00 BST Shire Launches Spotlight on Gaucher Film Contest and Calls for Video Entries Sharing Experiences of Living with Gaucher Disease

The contest aims to unite people impacted by Gaucher disease and raise awareness of this rare condition Gaucher disease is an inherited rare disease...


15 Jun, 2015, 12:00 BST Shire Names Bill Mordan General Counsel and Corporate Secretary; Appoints Michele Galen Head of Communications and Public Affairs

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Bill Mordan as General Counsel and Corporate Secretary, reporting to CEO Flemming...


11 Jun, 2015, 07:00 BST Shire Appoints Olivier Bohuon to its Board of Directors

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Olivier Bohuon to the Shire Board of Directors as a Non-Executive Director. Olivier...


03 Jun, 2015, 07:00 BST Shire Receives European Approval to Use Resolor® (prucalopride) in Men for the Symptomatic Treatment of Chronic Constipation

For Release in Europe Only Resolor was approved in 2009 in Europe for use in women for the symptomatic treatment of chronic constipation in whom...


26 May, 2015, 07:00 BST New Shire Research to be Presented at World Congress on ADHD Highlights Treatment Portfolio, Pipeline and Caregiver Experiences

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that new data advancing the understanding of attention deficit/hyperactivity disorder (ADHD) will...


06 May, 2015, 15:26 BST Shire to Participate at the Deutsche Bank 40th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Deutsche Bank 40th Annual Healthcare Conference in Boston, MA on...


04 May, 2015, 12:00 BST Shire and Foundation Fighting Blindness Announce New Research Agreement

For Rare Eye Disease First Appearing in Childhood or Adolescence Shire plc (LSE: SHP, NASDAQ: SHPG) and the Foundation Fighting Blindness today...


30 Apr, 2015, 12:01 BST Jeff Poulton Appointed Shire Chief Financial Officer and Joins Board of Directors

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Jeff Poulton as Chief Financial Officer (CFO) and member of the Executive Committee....


30 Apr, 2015, 12:00 BST Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS

- Continued Advancement Toward Goal of Becoming a Leading Global Biotechnology Company Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for ...


09 Apr, 2015, 18:55 BST U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has accepted for filing the New Drug...


09 Apr, 2015, 07:00 BST Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not meet...


07 Apr, 2015, 07:00 BST Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

Potential Launch of SHP465 Anticipated in Second Half of 2017 Exclusivity for Shire's Overall ADHD Product Portfolio Extends to 2029 Shire plc (LSE:...


06 Apr, 2015, 13:00 BST Shire Comments on USPTO Petitions Related to LIALDA and GATTEX

Shire plc (LSE: SHP, NASDAQ: SHPG) acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman...


02 Mar, 2015, 12:00 GMT Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug...


25 Feb, 2015, 14:00 GMT Shire to Present at the Cowen 35th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Flemming Ornskov, MD, Chief Executive Officer, will present at the Cowen 35th Annual...